Shiqin Liu

Shiqin Liu is an Assistant Adjunct Professor at the University of California, Los Angeles (UCLA) in the Department of Molecular and Medical Pharmacology. As a clinician-scientist with translational focus, their work bridges clinical practice and cancer research through biomarker development and therapeutic innovation.

• MD, Central South University (2012)
• PhD in Oncology, Peking University (2017)
• Joint PhD, University of Miami (2016)
• Residency in Surgery, Central South University (2019)
• Postdoctoral Fellow, Stanford University (2019-2023)
• Postdoctoral Fellow, UCLA (2023)

Their research focuses on identifying molecular drivers of cancer progression and developing clinical-grade diagnostic tools and therapies. Key areas include:

• Proteomics-based biomarker discovery for high-risk cancers
• Antibody-targeted therapies and imaging agents
• Mechanistic studies of neuroendocrine prostate cancer
• 3D tumor modeling and optical diagnostics

Recent publications highlight their work on:

• Trop2 as a prognostic urinary biomarker for prostate cancer
• UCHL1's dual role in tumor growth and therapeutic targeting
• Novel drug targets like CDC7 and CXCR4/CB2 heterodimers
• Biofabrication techniques for cancer modeling

Laboratory affiliations include:

• Stoyanova Lab at UCLA (2023-present)
• Stoyanova Lab at Stanford University (2019-2023)